Alzheimer's Is A Repeat Target For FDA Breakthrough Device Path
Executive Summary
NeuroDiagnostics LLC said its investigational Alzheimer's disease test had been designated by US FDA as a Breakthrough Device. This is at least the third company to achieve that recognition for technology targeting Alzheimer's this year.
You may also be interested in...
Jeff Shuren Talks Breakthrough Bonanza, TPLC And Innovating Safety
In an interview at The MedTech Conference in Philadelphia this week, US FDA device-center Director Jeff Shuren spoke to Medtech Insight about what is happening with the pending total product lifecycle office and the larger-than-expected response to the Breakthrough Devices Program. He also makes the point that supporting innovation and protecting safety are not opposing goals, and more.
Two Roche Alzheimer’s Assays Win US FDA Breakthrough Device Status
The company is getting its data ready for submission to FDA for the Elecsys cerebrospinal fluid assays and hopes the new Breakthrough Device designation will increase interaction with the agency and speed the path to approval.
FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.